idea-003 · human · US

ctDNA Assay Reference Panel

Quality control material — intended for use by molecular laboratories to monitor the analytical performance (analytical sensitivity at defined low tumor fractions, specificity, and inter-run precision) of tumor-informed circulating tumor DNA minimal residual disease assays, during assay validation and in routine run-by-run quality control. Not a calibrator, and not for use in establishing or interpreting an individual patient result.

Finished enough to read, and waiting for you. 7 of 7 departments answered: 7 conditional, none blocking. 32 of 192 claims verified, 2 refuted. 2 of 8 things it rests on are critical and open; the first is cheap to find out.

Open the decide panel →wrappedposture: evidence-gated status: wrapped updated 2026-09-26 Ask or request work ↗

The bet

In plain words

Quality-control samples sold to the laboratories that run blood tests for cancer left behind after treatment. Those tests look for a few tumour DNA fragments among a very large number of normal ones, and a lab has to show, before and during routine use, that its test still detects a signal that faint. Today labs mostly make their own control samples, or buy commercial ones built from cell-line DNA in an artificial liquid. This product is made from pooled human donor plasma instead, so it should behave more like a real patient sample, with known amounts of tumour DNA added at levels fainter than the commercial products document. It comes in two forms: a multi-level panel used when a lab validates its test, and a single-level vial the lab runs alongside patient samples on each testing day. The faintest levels are too faint to measure directly, so they are made by carefully weighed dilution from a measured stronger level and labelled as calculated rather than measured. It is sold as a regulated quality-control product under an existing FDA (US Food and Drug Administration) category for cancer DNA controls that does not need premarket clearance — whether that exemption actually applies to this product is an FDA question nobody has asked yet. No insurer pays for it; the labs buy it from their own budgets.

The same bet, precisely — in the assessment's words, with every claim it cites

A laboratory running a tumor-informed MRD (molecular residual disease) assay has to show, before it reports patients and then on every run, that the assay still detects tumor DNA at the fractions it claims. CLIA (Clinical Laboratory Improvement Amendments) requires control procedures that monitor the complete analytic process claim 7verified. It names no material for doing so claim 76verified, claim 77verified. So labs today make their own contrived controls, or dilute the one incumbent product with sub-0.1% levels, which is purified DNA in buffer claim 111unconfirmed, into their own plasma. The bet is that such a lab pays $400-$900 a vial for a single-use daily control, and $1,500-$3,000 for a validation panel claim 149unconfirmed. The material is built in pooled donor plasma, so it goes through extraction alongside the patient samples claim 187unconfirmed. It carries a stated uncertainty at every level, and it is listed as a Class II (FDA device class II) QC (quality control) device under product code SCU (subcutaneous), which FDA marks 510(k) (premarket notification)-exempt claim 131verified. The recurring money is the daily control claim 151unconfirmed. That line is the reason P2 clinical QC material at launch chose a clinical-QC label over an RUO (research use only) one, and it is also the line the RUO label disclaimed. The buyers are the thirty to sixty US labs running or developing these assays claim 12unconfirmed. The structural attraction is that no incumbent sells a plasma-matrix level below 0.1% claim 188unconfirmed. The structural danger is that the whole bet sits on one sentence, and the sentence has to satisfy three parties at once. FDA has to read it as exempt. The physics has to support its per-vial claims. A tumor-informed lab has to be able to run a control whose variants are not its patient's.

The assessment →

In the Wrap's one-paragraph version, written for someone who has not opened the file. Domain: ctdna-mrd-assay-validation

Who pays

One cheque, written by a laboratory out of its own budget. There is no payer leg for the product: nobody bills a payer for a control material, and the product has no code claim 55unconfirmed claim 14unconfirmed. P2 clinical QC material at launch changes who inside the laboratory the product is sold to, not that.

  • Writes the cheque: two buyers, one per SKU. The daily-use single-level control is bought by CLIA laboratories that report patient tumor-informed MRD results and run a control on every run claim 151unconfirmed claim 177unconfirmed. The **multi-level validation panel** is bought by those laboratories and by assay developers that report no patient results (IVD (in vitro diagnostic) kit makers, pharma and CRO assay groups, academic labs) claim 150unconfirmed claim 154unconfirmed. Whether either buyer can order it as a bench consumable rather than through capital procurement is claim 26unconfirmed; under P2 clinical QC material at launch the daily control is the easier case for that and the panel is not.
  • Out of which budget line: the laboratory's QC-consumables operating budget, which is funded by what the laboratory is paid for the test the control monitors. That is the only checked money in this chain, and it belongs to the customer: Medicare pays $3,590.00 per 0340U service on the CLFS (clinical laboratory fee schedule) claim 71verified, on 25,746 Medicare FFS (fee-for-service) services in CY2024 claim 68verified, with 0356U and 0422U at $1,800.00 and $1,943.21 claim 74verified on 4,481 and 243 services claim 75verified. Four active MolDX MRD articles list 0340U claim 72verified claim 73verified, which is existence, not coverage; that L38779 (a Medicare local coverage determination number) gives criteria-gated coverage is claim 136unconfirmed. None of this is the product's revenue, and none of it is a market size.
  • Against which comparator: four things a laboratory does today.
    • It builds its own contrived controls claim 21unconfirmed.
    • It dilutes an incumbent buffer-format material into its own plasma. The Seraseq ctDNA (circulating tumour DNA) MRD Panel Mix is four 200 ng vials at 0%, 0.5%, 0.05% and 0.005% tumor fraction in TE buffer claim 111unconfirmed, at $1,919.59 on a distributor web page claim 117unconfirmed, and diluting its 0.05% level costs roughly $80 per run claim 177unconfirmed.
    • It buys an RUO plasma-format control. AcroMetrix Multi-Analyte ctDNA Plasma Control A shows $490.00 on one storefront and $1,617.00 on another for the same vial claim 123unconfirmed claim 124unconfirmed.
    • It buys a listed 866.5910 control. Illumina lists oncology DNA/RNA controls under SCU claim 132unconfirmed, and a third party lists BCR-ABL1 monitoring controls under QIG claim 155unconfirmed. Neither listing has been read by any connector.
  • Stops buying instead: nothing is forced off the bench. CLIA requires the laboratory to run control material every day for molecular amplification claim 7verified but names no material, source or traceability for either the controls or the LoD study claim 76verified claim 77verified. What P2 clinical QC material at launch would displace is a particular material, whether in-house, a diluted buffer mix or an RUO plasma control. Whether it does is claim 177unconfirmed for the control and claim 153unconfirmed for the panel.

The payer-side pull is unread, and it is the one that would matter. If MolDX's technical assessment required LoD to be shown on known-VAF (variant allele frequency) material, a payer would be pulling this product without paying for it. That L38779 requires a technical assessment is claim 126unconfirmed. That its analytical-validity criteria require known-VAF material without naming a source is claim 137unconfirmed. That the TA FAQs permit purchased material is claim 165unconfirmed. The BLOODPAC contrived-sample functional characterization requirement is claim 164unconfirmed. Four documents, none read by a connector. Until one is read, the only verified demand driver is CLIA's, and it points at no supplier.

The business case →

What would kill it

What this idea rests on that is not yet known, in the order this idea's own decision queue puts it: worst if false first, cheapest to settle first inside that. The first row is open; open any other for what would settle it.

verifiedunconfirmedrefutednot yet checked
B1 A cancer-testing laboratory has to be willing to buy an outside quality- control sample and run it with every batch, build and maintain a dedicated test panel for it, accept it as meeting its quality rules, and pay for it rather than make its own. If labs will not, there is no customer.
Precisely: A laboratory running a tumor-informed MRD assay can and will run a purchased third-party control as its routine run-by-run control. That means designing and maintaining a dedicated panel against the control's certified variants, accepting that panel as meeting its control requirement, and paying for it instead of diluting incumbent material or making its own
 critical fatal if false standing: open 7 unconfirmedto find out: cheap

What would settle it (cheap): the REQ-0038 Run a short structured survey of 10-15 MRD…/REQ-0086 Extend the REQ-0038 survey instrument…/REQ-0098 Before the REQ-0038/REQ-0086 survey is…/REQ-0105 Before the REQ-0038/REQ-0086/REQ-0098… survey instrument fielded to 10-15 MRD lab directors, with one added question on how their run controls meet CLIA when every patient's panel differs; plus a literature read of published tumor-informed MRD validations for how their run-level controls are built (claim 190unconfirmed)

The 7 claim(s) it rests on

claim 21unconfirmed, claim 162unconfirmed, claim 177unconfirmed, claim 185unconfirmed, claim 187unconfirmed, claim 190unconfirmed, claim 191unconfirmed

The assessment's reasoning →

B5 There have to be enough laboratories, buying enough vials a year, at a price at or above today's incumbent, to cover the full cost including a permanent quality system. If the volumes or prices are too low, there is no business.
Precisely: It is a business. Enough labs, enough recurring control volume not held by one laboratory, and prices at or above the incumbent anchor clear the fully loaded cost, including a fixed quality-system layer, at planning volumes of about 50 panels and 2,000 vials a year
 critical fatal if false standing: open 13 unconfirmedto find out: project

What would settle it (project): the same survey as B1 A laboratory running a tumor-informed MRD… for price and volume, a written SeraCare quote (REQ-0087 Obtain a written quote from SeraCare/LGC…), a directory count of the labs (REQ-0037 Obtain a licensed lab-economics report on…), Operations' cost build-up at Commercial's volumes (REQ-0083 Produce the cost-of-goods build-up your…), and a count of Medicare MRD volume by laboratory from the cached CMS (Centers for Medicare & Medicaid Services) utilization file (claim 192unconfirmed)

The 13 claim(s) it rests on

claim 12unconfirmed, claim 26unconfirmed, claim 47unconfirmed, claim 49unconfirmed, claim 125unconfirmed, claim 140unconfirmed, claim 149unconfirmed, claim 150unconfirmed, claim 151unconfirmed, claim 152unconfirmed, claim 154unconfirmed, claim 178unconfirmed, claim 192unconfirmed

The assessment's reasoning →

B8 Something beyond the lab's own preference, a payer rule, an accreditation checklist, an industry consensus, or test revenue big enough to fund it, has to push labs toward buying characterised outside controls. If nothing does, adoption is slower and the business thinner.
Precisely: Something outside the lab's own preference pulls it toward characterized third-party material. Candidates are a payer technical assessment, the CAP checklist, the BLOODPAC consensus, or downstream test revenue large enough to fund QC spend
 high costly if false standing: holed 5 verified, 1 refuted, 9 unconfirmedto find out: cheap

What would settle it (cheap): four document retrievals already raised: the LCD (local coverage determination) L38779 text (REQ-0072 Retrieve active MolDX LCD L38779), the MolDX TA FAQs (REQ-0093 Retrieve Palmetto GBA's MolDX Technical…), the BLOODPAC full text (REQ-0103 Retrieve the full text), and the CAP MOL checklist (REQ-0028 Read ISO 17034)

The 15 claim(s) it rests on

claim 10refuted, claim 11unconfirmed, claim 15unconfirmed, claim 55unconfirmed, claim 57unconfirmed, claim 66verified, claim 68verified, claim 71verified, claim 76verified, claim 77verified, claim 136unconfirmed, claim 137unconfirmed, claim 144unconfirmed, claim 164unconfirmed, claim 165unconfirmed

The assessment's reasoning →

B7 No competitor's patent covers the material, the dilution method or the labelled use; the plasma and the synthetic DNA can lawfully be bought and sold; and the method is patentable. If a patent blocks it, the product changes or needs a licence.
Precisely: Nothing stands between the product and a lawful sale, and there is something to own. No incumbent patent reads on the material, the dilution chain or the labelled run-by-run use. The plasma, the spike line and the proxy DNAs can lawfully be sold, characterized and disclosed. The dilution-chain combination is patentable
 high reshaping if false standing: open 8 unconfirmedto find out: project

What would settle it (project): counsel's freedom-to-operate and patentability search over the P1 derived-value bottom levels/P2 clinical QC material at launch method (REQ-0027 Run a patent/prior-art landscape search, REQ-0097 Supplement REQ-0027's landscape to the…), with the three granted claim sets from USPTO (United States Patent and Trademark Office) full text first (REQ-0077 Attach from USPTO full text), and the supplier and line terms (REQ-0078 Name the pooled human donor plasma supplier, REQ-0085 Name the variant-bearing source material…, REQ-0108 Extend REQ-0085's licence enquiry for the…)

The 8 claim(s) it rests on

claim 143unconfirmed, claim 145unconfirmed, claim 146unconfirmed, claim 147unconfirmed, claim 148unconfirmed, claim 174unconfirmed, claim 175unconfirmed, claim 176unconfirmed

The assessment's reasoning →

B3 Every very dilute level of the control has to carry a value a lab can trust, and that value has to hold from the factory to the lab bench and from one production lot to the next. If it cannot, the product is not a reference material, and proving it is a funded, year-long piece of work.
Precisely: Every level below 0.1% can carry a defensible assigned value, and that value survives to the customer's bench. This includes the 0.03% daily control, assigned in one gravimetric step. It means a dilution-chain uncertainty within budget, enough molecules per vial summed over a stable clonal variant set, low enough background in the pool, independent confirmation by aggregate sequencing, stability, and three-lot consistency, at a level where an in-control run does not miss
 high reshaping if false standing: open 14 unconfirmedto find out: funded

What would settle it (funded): the pilot lot Technology specified in its REQ-0082 Specify the single pilot-lot bench… answer (WP0-WP2 and WP5), priced by REQ-0095 Price, as a cost and calendar with named… at a judgement band of USD 0.5-0.9M and 9-12 months to a pass/fail

The 14 claim(s) it rests on

claim 32unconfirmed, claim 60unconfirmed, claim 63unconfirmed, claim 133unconfirmed, claim 134unconfirmed, claim 138unconfirmed, claim 139unconfirmed, claim 160unconfirmed, claim 166unconfirmed, claim 167unconfirmed, claim 168unconfirmed, claim 169unconfirmed, claim 170unconfirmed, claim 186unconfirmed

The assessment's reasoning →

B2 Making the control out of real pooled human plasma, rather than a buffer, has to be a difference labs can measure and will pay extra for, with no competitor shipping the same thing first. If not, the product competes on price with what already exists.
Precisely: The native pooled-plasma matrix is a real, paid-for difference. Spike fragments recover like endogenous cfDNA across the extraction kits labs use. The material is more commutable than buffer-format incumbents. Pooled plasma can be sourced consistently. Buyers pay a premium for it. No incumbent ships the same thing first
 moderate reshaping if false standing: partial 2 verified, 6 unconfirmedto find out: project

What would settle it (project): a three-kit extraction-recovery comparison of spiked fragments against endogenous cfDNA (cell-free DNA) in purchased pooled plasma (Technology's WP3), run before any commutability study, which is REQ-0109 Source and cost the commutability and…'s EP30 design

The 8 claim(s) it rests on

claim 30unconfirmed, claim 31unconfirmed, claim 90verified, claim 92verified, claim 135unconfirmed, claim 153unconfirmed, claim 183unconfirmed, claim 188unconfirmed

The assessment's reasoning →

B4 The product has to fit inside an existing FDA exemption for laboratory quality-control materials, so that it can be sold without a clearance. If the FDA reads the intended use differently, the route becomes a clearance and the timeline and budget change.
Precisely: The P2 clinical QC material at launch intended-use sentence, the plasma matrix and the restricted label all sit inside 866.5910's 510(k) exemption. That means no neoplastic-disease withdrawal, no different-intended-use reading, "during assay validation" read as monitoring, and FDA accepting the special control's performance testing on LDTs, since no tumor-informed MRD assay is cleared
 moderate reshaping if false standing: partial 1 verified, 9 unconfirmedto find out: project

What would settle it (project): the 513(g) request drafted as REQ-0081 Draft the 21 CFR 513, filed after Regulatory answers REQ-0104 P2's intended-use sentence names… (label restriction against the sentence) and REQ-0090 Under the 866.5910 special control (derived values, LDT (laboratory-developed test) sites)

The 10 claim(s) it rests on

claim 52unconfirmed, claim 53unconfirmed, claim 131verified, claim 132unconfirmed, claim 155unconfirmed, claim 156unconfirmed, claim 157unconfirmed, claim 161unconfirmed, claim 163unconfirmed, claim 189unconfirmed

The assessment's reasoning →

B6 A company can build, or contract out, the quality system, the required studies and the first three production lots on the budget and timeline assumed. If it costs much more, the same business is slower and more capital-hungry.
Precisely: A company can build the P2 clinical QC material at launch fixed layer from a standing start, or buy it from a contract manufacturer, on the budget and calendar claim 20unconfirmed implies. The layer is a part 820 QMS, the special-control study set and three production lots on independently sourced pools, plus the plasma volume and screening those lots consume
 low costly if false standing: partial 4 verified, 11 unconfirmedto find out: cheap

What would settle it (cheap): retrieval of FDA's 2007 cystic-fibrosis QC special-controls guidance (REQ-0102 Retrieve FDA's 'Class II Special Controls…), then Regulatory's answer on whether its studies must precede distribution (REQ-0096 Under 21 CFR 866.5910 as a 510), then one contract-manufacturer quote (REQ-0100 For each FDA-registered establishment that…)

The 15 claim(s) it rests on

claim 20unconfirmed, claim 33unconfirmed, claim 58verified, claim 59verified, claim 61verified, claim 141unconfirmed, claim 142unconfirmed, claim 158unconfirmed, claim 159verified, claim 171unconfirmed, claim 172unconfirmed, claim 173unconfirmed, claim 179unconfirmed, claim 180unconfirmed, claim 181unconfirmed

The assessment's reasoning →

Each row is one thing this idea has to be true. Ordered by what a failure would cost and, inside that, by what it costs to find out — for this idea only; bands never compare between ideas.

What the departments said

Seven chairs, each answering from its own field. The verdict, and the first condition it set.

RegulatoryconditionalC3 A quality control material whose purpose is validating and monitoring a tumor-informed ctDNA MRD assay is not itself "intended for use in the diagnosis, monitoring, or screening of neoplastic… +8 more condition(s) the position →
Clinical & ScientificconditionalC2 A commutability study of EP30 design (difference-in-bias or regression against native clinical specimens) in which this panel behaves like patient plasma across at least two distinct tumor-informed… +8 more condition(s) the position →
Market AccessconditionalC1 No CPT (Current Procedural Terminology)/HCPCS code, NCD (national coverage determination), LCD or Medicare/Medicaid coverage determination applies to a commutable patient-matrix reference material panel of this kind, because it is purchased by a laboratory as an… +6 more condition(s) the position →
Technology & R&DconditionalC1 The panel's levels below 0.1% VAF can be value-assigned by gravimetric dilution from a dPCR (digital polymerase chain reaction)-quantified parent at or above 0.1% into a diluent whose wild-type cfDNA copy concentration is… +12 more condition(s) the position →
Operations & NPIconditionalC1 Pooled human donor plasma can be sourced at a scale and lot-to-lot consistency that preserves the native cfDNA fragmentomic profile the product's differentiation depends on. Under P2 clinical QC material at launch this is also a… +15 more condition(s) the position →
Legal & IPconditionalC1 No live, enforceable US patent held by an incumbent cfDNA/ctDNA reference-material or liquid-biopsy manufacturer (LGC/SeraCare, Revvity/Horizon, Twist, Natera, Guardant, Illumina/Grail, Roche… +7 more condition(s) the position →
CommercialconditionalC1 The reference-material spend pool for tumor-informed ctDNA MRD assay validation and run control is correctly sized top-down, as a share of downstream Medicare CLFS test revenue, rather than bottom-up… +14 more condition(s) the position →

A position is not evidence: it cites the file's tags and issues none. blocks opens an impact review and kills nothing.

What has been checked

The count

32/192
claims verified
2
refuted
9/9
factors scored
4/4
core factors
verifiedunconfirmedrefutednot yet checked

Only verified counts toward a score. A low count is usually a statement about the tooling — an absent data file, an unset key — rather than about the idea.

The claim ledger → · the nine factors ↓

What was found to be false

2 claim(s) the Verifier found to be false — a refuted claim is a finding, and the loop owes each one an answer.

What to do next

The next move

score-mover: vendor spec sheets/CoAs (Factor 8); decision-mover: B1 A laboratory running a tumor-informed MRD… lab-director survey. Two tests, answering different questions:

They differ, and the difference is information. The first would move a number on the scorecard. The second decides whether anyone would buy the daily vial that P2 clinical QC material at launch made the centre of the product.

Decisions on the table

Shortlist review — yours, at Stage 6
The packet is wrapped, which means it is finished enough to read — not that anything has judged it. Approve, reject or defer is a human act and is recorded only by a person.

Open the decide panel →

34 open questions between departments
All of them →

Go deeper

Assessmentthe bet, how it can fail, what each failure costsThe debateeach department's position, what failed, how the shape changedAll 192 claimsevery claim with its confidence tag and sourceStorythe whole thing as one narrativeDesirability deckwhat would have to be true — for the userViability deckwhat would have to be true — for the investorFeasibility deckwhat would have to be true — for engineeringBusiness casewho pays, how much, routes to revenueInvestor messageeach line bound to its claimUser messageeach line bound to its claimPayer messageeach line bound to its claimDomain dossierctdna mrd assay validationSearch inside this ideaevery section of every file about it
Where it stands in the machine stage verified · in the front-end loop · assessed — every stage this idea has been through, and what each holds
Running alongside every stage

A human decision, and only a human's

No human review is recorded. Shortlisting, legal and clinical sign-off and capital allocation are Tier 3: no agent in this repo makes or simulates one. The packet is wrapped, so it can be read now.

Click any step to see what it holds for this idea. donecurrentloopinghuman only

The full packet the whole ## Wrap section, as written

The packet a human reads. See docs/wrap-spec.md. This section says nothing about whether the idea is good — it says the file is finished enough to be read, and names what to do next. Filling it in advances no candidate and approves nothing.

Rewritten 2026-09-26 against the file as it now stands: pivot P2 clinical QC material at launch, 192 claims, the re-run Gate Check and the assessment. The previous version described the P0 the original shape research-use-only product and a 46-claim file, and is superseded in full.

The one-paragraph version. Quality-control samples sold to the laboratories that run blood tests for cancer left behind after treatment. Those tests look for a few tumour DNA fragments among a very large number of normal ones, and a lab has to show, before and during routine use, that its test still detects a signal that faint. Today labs mostly make their own control samples, or buy commercial ones built from cell-line DNA in an artificial liquid. This product is made from pooled human donor plasma instead, so it should behave more like a real patient sample, with known amounts of tumour DNA added at levels fainter than the commercial products document. It comes in two forms: a multi-level panel used when a lab validates its test, and a single-level vial the lab runs alongside patient samples on each testing day. The faintest levels are too faint to measure directly, so they are made by carefully weighed dilution from a measured stronger level and labelled as calculated rather than measured. It is sold as a regulated quality-control product under an existing FDA category for cancer DNA controls that does not need premarket clearance — whether that exemption actually applies to this product is an FDA question nobody has asked yet. No insurer pays for it; the labs buy it from their own budgets.

What would have to be true, quoted verbatim from each deck's load-bearing condition:

  • Desirability: "whether at least one in ten US laboratories running tumor-informed MRD assays would use this daily control as their run-by-run external control, at $400-$900 per vial, in place of in-house material, including material they could make by diluting the buffer-format incumbent into their own plasma for roughly $80 a run claim 177unconfirmed."
  • Viability: "whether, at the file's own planning volumes (50 panels and 2,000 daily vials a year) and the low end of its own prices, annual revenue of about $875,000 exceeds the fully loaded cost of goods plus the recurring cost of the 866.5910 obligations claim 178unconfirmed. The cost side of that comparison has no figure anywhere in the file."
  • Feasibility: "whether each panel level below 0.1% VAF can be value-assigned by gravimetric dilution from a dPCR-quantified parent into a dPCR-quantified diluent with an expanded uncertainty (k=2) of no more than 35% relative that includes dilution, between-unit heterogeneity and a characterized limit-of-blank term, and be labelled as derived rather than measured claim 134unconfirmed."

Alongside them, the top two pillars of the assessment's decision queue (knowledge-base/assessments/idea-003.md, posture evidence-gated) — the ones the business dies without:

  • B1 A laboratory running a tumor-informed MRD… critical, open — "A laboratory running a tumor-informed MRD assay can and will run a purchased third-party control as its routine run-by-run control. That means designing and maintaining a dedicated panel against the control's certified variants, accepting that panel as meeting its control requirement, and paying for it instead of diluting incumbent material or making its own"
  • B5 It is a business. Enough labs critical, open — "It is a business. Enough labs, enough recurring control volume not held by one laboratory, and prices at or above the incumbent anchor clear the fully loaded cost, including a fixed quality-system layer, at planning volumes of about 50 panels and 2,000 vials a year"

Cheapest next test: score-mover: vendor spec sheets/CoAs (Factor 8); decision-mover: B1 A laboratory running a tumor-informed MRD… lab-director survey. Two tests, answering different questions:

They differ, and the difference is information. The first would move a number on the scorecard. The second decides whether anyone would buy the daily vial that P2 clinical QC material at launch made the centre of the product.

Where the evidence actually stands. wrap_status.py reports 32 of 192 claims verified, 158 unconfirmed, 2 refuted (verified by class: 10 registry fact, 10 published finding, 12 unstamped). It also reports 9/9 factors and 4/4 core factors scored, which counts the Stage 2 triage table. The Verified Composite is narrower: 7/9 factors, 3/4 core, composite 46.3/100. Reimbursement and Strategic fit are blank for want of a referent, not scored 0. The Gate Check cleared at 7/9 with no kill condition firing. Cleared is not an approval. TAM sits exactly on its 2/5 floor, and every verified figure under it sizes the customers' test, not this product: 25,746 Medicare-FFS services for 0340U claim 68verified at a CY2026 CLFS rate of $3,590.00 claim 71verified. The earlier >100,000 volume is refuted claim 10refuted. The launch code, SCU under 866.5910, is verified to exist and to be 510(k)-exempt claim 131verified, and the quality-system obligations it brings are verified claim 159verified. Whether the exemption applies is not verified.

What is blocked on tooling rather than on a finding — none of these absences is evidence that the thing does not exist:

What is blocked on a finding, or on work nobody can do from a desk: the product's own units, price, capture and cost claim 149unconfirmed claim 150unconfirmed claim 151unconfirmed claim 178unconfirmed need customer interviews and a cost build-up. The sub-0.1% value-assignment budget claim 134unconfirmed needs a pilot lot on the bench. Whether the 866.9 exemption limbs withdraw the exemption claim 52unconfirmed claim 53unconfirmed is an FDA judgment that only a 513(g) response settles. Filing it is a human spend decision. The adverse finding on file that bears on the business is the refuted volume claim 10refuted; the other refutation claim 70refuted only corrects how a CMS file is distributed and moves nothing.

The nine factors why each scored what it did, and what would settle it
FactorScoreWhyWhat would settle it
Regulatory pathway3Both halves scored. Upside: RUO labeling per 809.10(c) sits outside premarket review entirely (claim 1unconfirmed) — no 510(k), no De Novo (De Novo classification request), no submission calendar, a real time-to-revenue advantage; the 862.1660 repositioning route is Class I and…
the rest of this reasoning largely 510(k)-exempt if ever taken (claims 4, 5). Downside, and why this is not a 4 or 5: the intended go-to-market — selling to CLIA labs to validate clinical tests — is precisely the marketing conduct the 2013 RUO/IUO guidance treats as defeating RUO status (claims 2, 3). That is a live misbranding exposure and a cap on what the product may claim, not a formality. claim 6verified (no 862.1660 product code identified) is an honestly recorded absence of evidence and is scored as neither support nor counter-evidence. All six rest on Generator memory; no primary text was read.
Human-attached eCFR text for 21 CFR 809.10(c), 862.1660, and 862.9 (free) settles the regulatory structure, and an openFDA product-code classification lookup (free) resolves claim 6verified for the clinical-QC SKU. FDA's 2013 RUO/IUO guidance PDF,…
the rest of this gap analysis pulled from fda.gov (free), is needed for the misbranding question — no connector reaches guidance documents.
Reimbursement pathwayn/a — not scoredDeliberately left blank, not zeroed. claim 14unconfirmed: this product has no CPT/HCPCS code and none is achievable — the buyer is a CLIA laboratory purchasing QC material as an operating input, and nobody bills a payer for a reference panel. A…
the rest of this reasoning HCPCS (Healthcare Common Procedure Coding System) connector returning nothing is the correct result here, not a gap. A 0 would misread as "reimbursement is bad" and would combine with Factor 1 under a kill condition written for human therapeutic devices (see Scorer's notes). The reimbursement linkage is real but indirect and second-order: customer test volume rides on the customer's own reimbursement (CPT 0340U, claim 8unconfirmed; MolDX article A58456, claim 13unconfirmed). That dependency is scored under TAM, where it belongs.
Nothing settles this factor directly — it does not apply to an RUO consumable. The indirect dependency needs the AMA-licensed PLA descriptor for 0340U (human-attached, licensing fee) and MolDX article A58456 opened in the CMS Medicare…
the rest of this gap analysis Coverage Database (free).
TAM2Claims 9-12 are the four TAM components; claim 7verified (CLIA 493.1256 control-procedure requirement) is the driver of recurring demand and claim 15unconfirmed (LDT rule vacatur) is a swing factor in both directions. Working the file's own numbers: ~100k…
the rest of this reasoning tests x $3,500 = ~$350M downstream Medicare test revenue, x 0.5-1.5% QC spend = ~$1.75-5.25M initial obtainable, across 30-60 labs. Components 3 and 4 are self-declared assumptions with no primary source; component 2 is an explicit order-of-magnitude guess. Even in the best case where every component verifies, a Medicare claim volume is a floor on US volume — excluding Medicare Advantage (Medicare Advantage), commercial, Medicaid, VA, and cash-pay — and is not itself a market size. Scored 2 because the arithmetic lands in low single-digit millions on the candidate's own assumptions; this sits exactly on the 2/5 kill floor.
CMS procedure-volume and payment-rate lookups (free, cached CMS files) settle components 1-2; components 3-4 need a licensed lab-economics report and a human-built MolDX/CAP/NY-CLEP lab enumeration. claim 15unconfirmed needs the ACLA v. FDA opinion…
the rest of this gap analysis and docket number attached (free, court record).
FTO / IP3claim 18unconfirmed states outright that no specific patent number was identified — an open research task, not a completed clearance search. The 3 is a placeholder for "nothing known to block," not a finding of freedom, and should be read as the…
the rest of this reasoning least-evidenced number in this table. The only positive inference available is weak and indirect: three vendors (claim 17unconfirmed) sell contrived cfDNA reference material commercially today, which suggests the base composition space is practiceable. Named residual risk sits in fragmentomic-profile preservation and low-VAF variant-spiking methods likely held by sequencing incumbents. Cannot currently be scored either blocked or clear.
A commissioned patent-landscape/FTO search report (screening LGC, Revvity/Horizon, Twist, Natera, Guardant, Illumina/Grail; several thousand dollars from a search firm) is the primary source; the patent connector alone only checks named…
the rest of this gap analysis patent numbers once one is identified.
Moat / defensibility2claim 19unconfirmed, which is the Generator's own judgment and concedes the key point: the material itself is reproducible by any competent competitor. The durable assets claimed are the orthogonal characterization dataset, traceability and…
the rest of this reasoning uncertainty documentation that drops into a CAP validation packet, and lot-to-lot continuity switching cost once a lab has anchored a published LoD claim to a lot. Real but non-exclusionary — they slow a fast-follower, they do not stop one. The whole moat is further contingent on claim 21unconfirmed, the explicitly unverifiable behavioral assumption that labs prefer a third-party panel to the in-house contrived controls they already build.
A human reading of ISO 17034 and the CAP Molecular Pathology (MOL) checklist (free, a few hours) settles whether third-party material is required or merely accepted; the lab-preference question needs primary customer-discovery interviews…
the rest of this gap analysis with named MRD lab directors.
Mechanism & clinical risk2claim 16unconfirmed, which the Generator itself names as the single largest technical risk: material with a stated uncertainty budget at 0.001%-0.01% VAF is Poisson-limited at typical 10-30 ng cfDNA inputs, so the lowest panel levels may be…
the rest of this reasoning irreducibly imprecise rather than merely hard to make. Clinical and patient risk are near zero — an in vitro reagent with no human exposure — so this factor is almost purely technical here. Scored low because the risk is aimed at exactly the differentiating range: higher-VAF levels are demonstrably manufacturable (competitors ship them, claim 17unconfirmed), and the sub-0.01% claim is the product thesis. First-principles reasoning only; no bench data exists.
An internal dPCR replicate series (wet-lab bench work, roughly low-single-digit thousands of dollars) directly settles this; a free PubMed literature scan can bound the answer first.
Capital intensity & time-to-revenue4claim 20unconfirmed (first revenue on a low-single-digit-million budget: small wet lab, digital PCR platform, donor plasma sourcing, ISO 17034-oriented documentation) reinforced by claim 1unconfirmed — no instrument development, no clinical trial, no premarket…
the rest of this reasoning submission, therefore no FDA review calendar between build and first invoice. The candidate's strongest factor and the main reason it is worth a Verifier pass at all. Held to 4 rather than 5 because the figure is the Generator's own estimate with no bill of materials behind it, and because ultra-low-VAF characterization is non-trivial wet-lab work whose true cost rides on the unresolved Factor 6 risk — if the bottom panel levels need heroic effort, this number moves down.
A human-attached bottom-up build plan settles this: dPCR platform quote, donor-plasma sourcing contract, A2LA ISO 17034 accreditation quote/calendar, and headcount plan — a handful of vendor quotes, largely free to obtain.
Competitive intensity2claim 17unconfirmed. Three well-capitalized incumbents — LGC Clinical Diagnostics (Seraseq), Revvity/Horizon Discovery, and Twist Bioscience — already sell cfDNA/ctDNA reference materials to exactly this buyer, with catalog presence, distribution,…
the rest of this reasoning and existing lab relationships. The claimed white space is the negative half of that claim (no product characterized in the sub-0.01% VAF MRD range on native fragmentomic patient matrix), which the Generator explicitly flags as weakly supported and asks to be checked hard. Even if the gap is real, it is a line extension any of the three could ship, not a barrier. Scored 2 = high intensity, unfavorable.
Vendor catalog spec sheets and certificates of analysis for Seraseq ctDNA, Revvity/Horizon HDx, and Twist cfDNA (free, publicly posted) settle the lowest-characterized-VAF gap; a free PubMed literature scan can corroborate independently.
Strategic fit & portfolio balance3Placeholder, no claim basis. No portfolio thesis document exists in this repo to score fit against, and docs/spec.md assigns strategic fit and portfolio balance to Stage 6 human judgment rather than to an agent. Scored on archetype…
the rest of this reasoning alone: a low-capital, fast-to-revenue, recurring-consumable picks-and-shovels play (claims 20, 7) riding a clinical market with an established reimbursement pathway underneath it (claims 8, 13) reads as a cash-generative spoke rather than a hero bet. That is a shape, not a fit.
A human-supplied portfolio-thesis or capital-allocation document naming the intended hero-bet vs. cash-generative-spoke mix (free to produce); no connector applies, since this is Stage 6 territory by design.
Packet status all eight wrap criteria met

All eight wrap criteria are met.

Source file: knowledge-base/candidates/idea-003.md

Nothing on this page is a recommendation. Shortlist review, legal and clinical sign-off and capital allocation are human-only decisions, and no agent in this repo may make or simulate one. This is a compilation of what the candidate file says.

Words on this page32 abbreviation(s) and code(s), with what each stands for — copied from _shared/plain-language.md
21 CFR
Title 21 of the Code of Federal Regulations — the US food-and-drug rulebook; a number after it is one regulation, often the one that classifies a device type
510(k)
premarket notification — the FDA route for a device shown to be as safe and effective as one already on the market; months, no clinical trial as a rule
cfDNA
cell-free DNA — DNA fragments floating in the blood, most of them from normal cells
Class II
FDA device class II — moderate-risk devices, usually cleared by 510(k)
CLFS
clinical laboratory fee schedule — the Medicare price list for laboratory tests
CLIA
Clinical Laboratory Improvement Amendments — the US rules a clinical laboratory must meet to report test results on patients
CMS
Centers for Medicare & Medicaid Services — the US agency that runs Medicare, and so decides what Medicare pays for
CPT
Current Procedural Terminology — the US billing codes for what a clinician does; owned by the American Medical Association
ctDNA
circulating tumour DNA — fragments of a tumour's DNA found in the blood
De Novo
De Novo classification request — the FDA route for a new, lower-risk device with no comparable product to point at; longer than a 510(k), usually needs clinical data
dPCR
digital polymerase chain reaction — a laboratory method that counts individual DNA molecules
EPO
European Patent Office — the European patent office
FDA
US Food and Drug Administration — the US regulator that clears or approves a device before it can be sold
FFS
fee-for-service — the traditional form of Medicare that pays per item or service
FTO
freedom to operate — whether a product can be sold without infringing someone else's live patent
HCPCS
Healthcare Common Procedure Coding System — the US billing codes for equipment, supplies and some services; a code is how a payer recognises what to pay for
IP
intellectual property — patents and the other rights that let a company stop others copying it
ISO
International Organization for Standardization — the body whose numbered standards devices and laboratories are tested against
IVD
in vitro diagnostic — a test run on a sample taken from the body rather than on the body
L#####
a Medicare local coverage determination number — the public id of one local coverage rule; the letter L and five digits
LCD
local coverage determination — a Medicare contractor's rule, valid in its region, saying when something is covered
LDT
laboratory-developed test — a test a laboratory builds and runs itself rather than buys
Medicare Advantage
Medicare Advantage — Medicare delivered through a private insurer; must cover at least what Medicare covers
MRD
molecular residual disease — cancer left behind after treatment, too little to see on a scan, detected through DNA in the blood
NCD
national coverage determination — a Medicare rule, valid everywhere in the US, saying whether and when something is covered
PMA
premarket approval — the FDA route for the highest-risk devices; years and clinical trials
QC
quality control — the samples and checks a laboratory runs to prove its test is still working
RUO
research use only — a labelling status that keeps a product out of patient diagnosis; no FDA review, no clinical claims
SCU
subcutaneous — under the skin
TAM
total addressable market — how much money the whole market would be worth if every possible buyer bought
USPTO
United States Patent and Trademark Office — the US patent office
VAF
variant allele frequency — what share of the DNA fragments at one position carry the tumour's mutation; the lower it is, the harder the test
Generated from knowledge-base/candidates/idea-003.md by engine/scripts/build_review.py on 2026-10-04. This page is a view — edit the source file and rebuild, never edit here.